? PILOT AND FEASIBILITY PROGRAM The Pilot Feasibility Program seeks to introduce new investigators and ideas to the Liver Center, to promote novel ideas that may advance the field of hepatology, and to enable investigators to obtain data for future grant submissions, such as R01 applications. Candidates for funding in order of priority consist of: (1) senior postdoctoral fellows and junior faculty; (2) established University investigators in other fields who wish to apply their areas of expertise to subjects of Center interest; and (3) Center members who wish to pursue a project that is different from their current focus of interest and who need to develop preliminary data to apply for new R01-type funding. Despite limited and essentially level funding for this program during the past 31 years, this component of the Center has provided us with an annual opportunity to solicit applications for pilot project awards from throughout the Yale community. This has enabled the Center to continually revitalize its membership and to capitalize on new technologies and research opportunities of importance to the continued development of the Center's research base. For example, during the past 6 years this program has enabled the Center to bring new investigators into the Center with expertise in diverse but cutting-edge areas. Pilot Feasibility projects also were pivotal for the development of novel technologies such as iPSC-derived cholangiocytes, as well as biliary organoids derived from liver tissue or bile. The program has been successful by a variety of other metrics: awardees over the past 11 years published 66 manuscripts as a direct result of their funding and competed successfully for 36 new grants, representing a 17-fold return on investment. In addition, 45 of the 46 awardees (including those who left Yale) remain involved in digestive diseases-related research. Moreover, in the last 12 years (including grants that were just awarded September 2019), 73% of the 37 Pilot/Feasibility awardees who are still at Yale remain active Center members.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK034989-36A1
Application #
10048273
Study Section
Special Emphasis Panel (ZDK1)
Project Start
1997-09-30
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
36
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Brivio, Simone; Cadamuro, Massimiliano; Fabris, Luca et al. (2018) Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expr 18:31-50
Cox, Carly S; McKay, Sharen E; Holmbeck, Marissa A et al. (2018) Mitohormesis in Mice via Sustained Basal Activation of Mitochondrial and Antioxidant Signaling. Cell Metab 28:776-786.e5
Madiraju, Anila K; Qiu, Yang; Perry, Rachel J et al. (2018) Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med 24:1384-1394
Schmitz, Corinna; Noels, Heidi; El Bounkari, Omar et al. (2018) Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis. FASEB J 32:4428-4443
Pan, Qiong; Zhang, Xiaoxun; Zhang, Liangjun et al. (2018) Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. Gastroenterology 155:1578-1592.e16
Jakab, Sofia Simona; Garcia-Tsao, Guadalupe (2018) Screening and Surveillance of Varices in Patients With Cirrhosis. Clin Gastroenterol Hepatol :
Fiorotto, Romina; Amenduni, Mariangela; Mariotti, Valeria et al. (2018) Src kinase inhibition reduces inflammatory and cytoskeletal changes in ?F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology 67:972-988
Sari, Sinan; Dalgic, Buket; Muehlenbachs, Atis et al. (2018) Prototheca zopfii Colitis in Inherited CARD9 Deficiency. J Infect Dis 218:485-489
Yu, Dongke; Cai, Shi-Ying; Mennone, Albert et al. (2018) Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int 38:1128-1138
Garcia-Tsao, Guadalupe (2018) Regression of HCV cirrhosis: Time will tell. Hepatology 67:1651-1653

Showing the most recent 10 out of 763 publications